ASX:VHT

Stock Analysis Report

NOT FOR DISTRIBUTION
Header cover image

Volpara Health Technologies

Executive Summary

Volpara Health Technologies Limited provides breast imaging analytics and analysis products for the early detection of breast cancer in the medical device and practice management software industry. More Details


Snowflake Analysis

Flawless balance sheet with limited growth.

Share Price & News

How has Volpara Health Technologies's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: VHT has not had significant price volatility in the past 3 months.


Market Performance


7 Day Return

5.6%

VHT

6.9%

AU Healthcare Services

-0.5%

AU Market


1 Year Return

-11.4%

VHT

5.3%

AU Healthcare Services

-6.2%

AU Market

Return vs Industry: VHT underperformed the Australian Healthcare Services industry which returned 1.6% over the past year.

Return vs Market: VHT underperformed the Australian Market which returned -5.4% over the past year.


Shareholder returns

VHTIndustryMarket
7 Day5.6%6.9%-0.5%
30 Day18.8%21.7%6.8%
90 Day7.1%28.7%4.4%
1 Year-11.4%-11.4%5.6%5.3%-2.9%-6.2%
3 Year131.1%129.5%237.5%234.0%17.9%2.9%
5 Yearn/a261.3%249.6%43.9%14.6%

Price Volatility Vs. Market

How volatile is Volpara Health Technologies's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is Volpara Health Technologies undervalued compared to its fair value and its price relative to the market?

6.78x

Price to Book (PB) ratio


Share Price vs. Fair Value

Below Fair Value: Insufficient data to calculate VHT's fair value to establish if it is undervalued.

Significantly Below Fair Value: Insufficient data to calculate VHT's fair value to establish if it is undervalued.


Price To Earnings Ratio

PE vs Industry: VHT is unprofitable, so we can't compare its PE Ratio to the XX Healthcare Services industry average.

PE vs Market: VHT is unprofitable, so we can't compare its PE Ratio to the Australian market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate VHT's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: VHT is overvalued based on its PB Ratio (6.8x) compared to the AU Healthcare Services industry average (5.6x).


Next Steps

Future Growth

How is Volpara Health Technologies forecast to perform in the next 1 to 3 years based on estimates from 3 analysts?

55.3%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: VHT is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: VHT is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: VHT is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: VHT's revenue (38.4% per year) is forecast to grow faster than the Australian market (4.6% per year).

High Growth Revenue: VHT's revenue (38.4% per year) is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: VHT is forecast to be unprofitable in 3 years.


Next Steps

  • Explore growth companies in the Healthcare industry.

Past Performance

How has Volpara Health Technologies performed over the past 5 years?

10.4%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: VHT is currently unprofitable.

Growing Profit Margin: VHT is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: VHT is unprofitable, but has reduced losses over the past 5 years at a rate of 10.4% per year.

Accelerating Growth: Unable to compare VHT's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: VHT is unprofitable, making it difficult to compare its past year earnings growth to the Healthcare Services industry (-4.5%).


Return on Equity

High ROE: VHT has a negative Return on Equity (-39.01%), as it is currently unprofitable.


Next Steps

Financial Health

How is Volpara Health Technologies's financial position?


Financial Position Analysis

Short Term Liabilities: VHT's short term assets (NZ$40.6M) exceed its short term liabilities (NZ$15.9M).

Long Term Liabilities: VHT's short term assets (NZ$40.6M) exceed its long term liabilities (NZ$4.8M).


Debt to Equity History and Analysis

Debt Level: VHT is debt free.

Reducing Debt: VHT currently has no debt however we can't compare to 5 years ago as we have no data for that period.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: VHT has sufficient cash runway for more than a year based on its current free cash flow.

Forecast Cash Runway: VHT has sufficient cash runway for more than 3 years if free cash flow continues to reduce at historical rates of 29.1% each year


Next Steps

Dividend

What is Volpara Health Technologies's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate VHT's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate VHT's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if VHT's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if VHT's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of VHT's dividend in 3 years as they are not forecast to pay a notable one for the Australian market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

1.0yrs

Average management tenure


CEO

Ralph Highnam

no data

Tenure

NZ$395,180

Compensation

Dr. Ralph Highnam, BSc (Hons) 1st Class, MSc, PhD, serves as the Group Chief Executive Officer and Managing Director at Volpara Health Technologies Limited . He is Founder of Volpara Health Technologies Li ...


CEO Compensation Analysis

Compensation vs Market: Ralph's total compensation ($USD263.14K) is below average for companies of similar size in the Australian market ($USD512.27K).

Compensation vs Earnings: Ralph's compensation has been consistent with company performance over the past year.


Leadership Team

NamePositionTenureCompensationOwnership
Ralph Highnam
MD, CEO & Directorno dataNZ$395.18k6.46%
NZ$ 24.9m
Craig Hadfield
CFO & Company Secretary3.58yrsNZ$320.51kno data
Monica Saini
Non-Executive Director & Chief Medical Officer2.17yrsNZ$247.65kno data
Nico Karssemeijer
Co-Founder & Member of Scientific Boardno datano data1.02%
NZ$ 3.9m
Simon Francis
Chief Operating Officer1.17yrsno datano data
Gareth Beaumont
Chief Information Officer & Chief Information Security Officer0.83yrno datano data
Kathryn Greene
Chief People Officer1.33yrsno datano data
Julian Marshall
Chief Knowledge Officerno dataNZ$510.51kno data
Mark Morris
Executive Vice President0.83yrno datano data
Matt Prickett
Senior Vice President of Productno datano datano data
Katherine Singson
Chief Executive Officer of Volpara Solutions Inc0.17yrno datano data

1.0yrs

Average Tenure

Experienced Management: VHT's management team is not considered experienced ( 1 years average tenure), which suggests a new team.


Board Members

NamePositionTenureCompensationOwnership
Ralph Highnam
MD, CEO & Directorno dataNZ$395.18k6.46%
NZ$ 24.9m
Monica Saini
Non-Executive Director & Chief Medical Officer2.17yrsNZ$247.65kno data
Nico Karssemeijer
Co-Founder & Member of Scientific Boardno datano data1.02%
NZ$ 3.9m
Roger Allen
Non-Executive Director10.33yrsNZ$69.15k7.36%
NZ$ 28.3m
Martin Yaffe
Member of Scientific Boardno datano data1.11%
NZ$ 4.3m
John Diddams
Independent Non-Executive Director5.75yrsNZ$150.62k0.61%
NZ$ 2.4m
John Pavlidis
Independent Non-Executive Director5.75yrsNZ$131.99k0%
NZ$ 0
Bruce Schroeder
Member of Medical Advisory Boardno datano datano data
Jennifer Harvey
Member of Medical Advisory Boardno datano datano data
Gerard den Heeten
Member of Medical Advisory Boardno datano datano data
Karin Lindgren
Independent Non-Executive Director0.75yrNZ$14.16kno data
Paul Robert Reid
Independent Non-Executive Chairman of the Board1.58yrsNZ$157.85kno data

5.8yrs

Average Tenure

Experienced Board: VHT's board of directors are considered experienced (5.8 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 15%.


Top Shareholders

Company Information

Volpara Health Technologies Limited's company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Volpara Health Technologies Limited
  • Ticker: VHT
  • Exchange: ASX
  • Founded: 2009
  • Industry: Health Care Technology
  • Sector: Healthcare
  • Market Cap: AU$385.007m
  • Shares outstanding: 250.82m
  • Website: https://volparasolutions.com

Number of Employees


Location

  • Volpara Health Technologies Limited
  • Simpl House
  • Level 14
  • Wellington
  • 6011
  • New Zealand

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
VHTASX (Australian Securities Exchange)YesOrdinary SharesAUAUDApr 2016
VHTCHIA (Chi-X Australia)YesOrdinary SharesAUAUDApr 2016
VPAH.FOTCPK (Pink Sheets LLC)YesOrdinary SharesUSUSDApr 2016

Biography

Volpara Health Technologies Limited provides breast imaging analytics and analysis products for the early detection of breast cancer in the medical device and practice management software industry. The com ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2020/10/22 10:38
End of Day Share Price2020/10/22 00:00
Earnings2020/03/31
Annual Earnings2020/03/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.